Boothbay Fund Management’s Gyre Therapeutics GYRE Stock Holding History

Boothbay Fund Management’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,122	Closed	-$30K	–	2422
2022 Q1	$30K	Hold	6,122	–	–	﹤0.01%	2220
2021 Q4	$42K	Hold	6,122	–	–	﹤0.01%	1781
2021 Q3	$189K	Sell	6,122 -2,735	-31%	-$90K	0.01%	1600
2021 Q2	$288K	Sell	8,857 -266	-3%	-$9.13K	0.01%	1311
2021 Q1	$345K	Buy	+9,123	New	+$417K	0.01%	1128
2020 Q3	–	Sell	-5,300	Closed	-$233K	–	1117
2020 Q2	$233K	Buy	+5,300	New	+$249K	0.02%	767
2018 Q3	–	Sell	-7,619	Closed	-$667K	–	845
2018 Q2	$667K	Buy	7,619 +4,332	+132%	+$760K	0.06%	267
2018 Q1	$636K	Buy	+3,287	New	+$613K	0.08%	261

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Boothbay Fund Management's GYRE Position: Q2 2022 in Review

Boothbay Fund Management sold out of Gyre Therapeutics (GYRE) in Q2 2022, closing a stake of 6,122 shares — an estimated $30K sold.

Boothbay Fund Management first reported a position in GYRE in Q1 2018 and held it in 8 quarters. The position peaked at $667K in Q2 2018. 41 funds tracked by Wall St. Rank hold GYRE as of Q2 2022.

Boothbay Fund Management reported no remaining Gyre Therapeutics position as of Q2 2022 after selling out during the quarter.
Boothbay Fund Management sold 6,122 Gyre Therapeutics shares in Q2 2022, an estimated $30K.
Boothbay Fund Management first reported a position in Gyre Therapeutics in Q1 2018 and held it in 8 quarters.
Boothbay Fund Management's Gyre Therapeutics position peaked at $667K in Q2 2018.
41 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.